The Kirkland Signature x Nike SB Dunk Low is now available for sale at select Costco ( COST ) locations, with a strong reception that is generating an unexpected surge in the price of the sneaker on resale markets. The shoe was “shock dropped” on Friday with a price tag of $134.99, but the buying frenzy and limited supply (Costco has limited purchases to one per customer) are translating into resale prices on third-party sites like eBay ( EBAY ), GOAT, and Stockx between $400 to as high as $1,000. The shoe is inspired by the popular Kirkland sweatshirt, featuring a grey cotton upper, Kirkland’s logo on the lateral heel and inner tongue, and a reverse insole that features an image of the Costco ( COST ) hotdog. Kirkland Signature x Nike SB Dunk (WWD) Costco ( COST ) teased the collaboration with Nike ( NKE ) last year but did not disclose the design or pricing, or even the intended launch date. The overwhelming success of the sneaker can largely be attributed to the popularity of the Kirkland Signature brand. Launched in 1995, Costco’s ( COST ) Kirkland brand consolidated all the retailer’s private label brands with a single name inspired by its Kirkland, Washington headquarters. Thanks to its high quality and affordably priced merchandise, the Kirkland brand consistently remains one of Costco’s ( COST ) highest grossing segments, generating ~$86B in sales, or roughly one-third of Costco’s total revenue. The brand frequently collaborates with other major brands, including Kirkland Signature Jelly Belly jelly beans, coffee blends with Starbucks ( SBUX ), and Duracell batteries. The Nike ( NKE ) collaboration, however, is already generating buzz as the most successful Kirkland partnership to date. More on Nike, Costco Nike: Too Little Room For Error Costco: Strong Start To 2026 Likely Short-Lived Costco: Sell The New Year Rally Nike retools an old line into a new outdoor performance brand The world’s strongest brands in 2025, ranked

In trading on Monday, shares of Qualys, Inc. (Symbol: QLYS) crossed above their 200 day moving average of $135.54, changing hands as high as $136.69 per share. Qualys, Inc. shares are currently trading up about 3% on the day. The chart below shows the one year performance of QLYS shares, versus its 200 day moving average: Looking at the chart above, QLYS's low point in its 52 week range is $112.61 per share, with $155.47 as the 52 week high point — that compares with a last trade of $135.76. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Analysts Are Bullish on These Technology Stocks: Paylocity (PCTY), Apple (AAPL) The Globe and Mail

Investors considering a purchase of Corvus Pharmaceuticals Inc (Symbol: CRVS) stock, but tentative about paying the going market price of $21.47/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $8 strike, which has a bid at the time of this writing of $1.60. Collecting that bid as the premium represents a 20% return against the $8 commitment, or a 10.2% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to CRVS's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $8 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Corvus Pharmaceuticals Inc sees its shares decline 62.9% and the contract is exercised (resulting in a cost basis of $6.40 per share before broker commissions, subtracting the $1.60 from $8), the only upside to the put seller is from collecting that premium for the 10.2% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Corvus Pharmaceuticals Inc, and highlighting in green where the $8 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 put at the $8 strike for the 10.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Corvus Pharmaceuticals Inc (considering the last 250 trading day closing values as well as today's price of $21.47) to be 122%. For other put options contract ideas at t...

AMD Likely to Exceed Q4 Estimates, Wedbush Says marketscreener.com

消息人士称，嘉能可接近授权花旗担任其与力拓集团合并谈判的顾问。（财联社）

Tesla’s $20 Billion AI Gamble: Inside the Pivot from Automaker to Robotics Titan FinancialContent

Tesla’s $20 Billion AI Gamble: Inside the Pivot from Automaker to Robotics Titan The Chronicle-Journal

In trading on Tuesday, shares of Warner Music Group Corp (Symbol: WMG) crossed above their 200 day moving average of $29.95, changing hands as high as $31.17 per share. Warner Music Group Corp shares are currently trading up about 0.6% on the day. The chart below shows the one year performance of WMG shares, versus its 200 day moving average: Looking at the chart above, WMG's low point in its 52 week range is $21.57 per share, with $38.755 as the 52 week high point — that compares with a last trade of $29.78. Click here to find out which 9 other stocks recently crossed above their 200 day moving average » Also see: The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Investors eyeing a purchase of Tandem Diabetes Care Inc (Symbol: TNDM) stock, but tentative about paying the going market price of $20.73/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2027 put at the $13 strike, which has a bid at the time of this writing of $1.75. Collecting that bid as the premium represents a 13.5% return against the $13 commitment, or a 14.2% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to TNDM's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $13 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Tandem Diabetes Care Inc sees its shares fall 37.4% and the contract is exercised (resulting in a cost basis of $11.25 per share before broker commissions, subtracting the $1.75 from $13), the only upside to the put seller is from collecting that premium for the 14.2% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Tandem Diabetes Care Inc, and highlighting in green where the $13 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2027 put at the $13 strike for the 14.2% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Tandem Diabetes Care Inc (considering the last 250 trading day closing values as well as today's price of $20.73) to be 79%. For other put options contract ideas at the vario...

Posts from this author will be added to your daily email digest and your homepage feed. Valentine’s Day often comes with more pressure than it needs to. At heart, though, February 14th is about showing appreciation for the people you care about in ways that feel thoughtful and sincere. And while big displays of romance can do that, it’s often the quieter, more personal gestures — or a meaningful gift that makes life just a little more enjoyable — that matter most. Below, we’ve rounded up gift ideas that, in our experience, do just that. Some are practical picks, like a pair of noise-canceling earbuds meant to help you focus or a pair of USB-C hand warmers for those cold, blustery days back east. Others, such as Renpho’s eye massager, are designed for rest and relaxation, while some of our more sentimental picks aspire to create a deeper, more lasting kind of romance. Whether you’re shopping for your wife, a close friend, a partner, or a girlfriend, these gifts are meant to make that special someone in your life feel seen, cared for, and appreciated — regardless of the day.

Investors eyeing a purchase of American Superconductor Corp. (Symbol: AMSC) stock, but tentative about paying the going market price of $30.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2027 put at the $18 strike, which has a bid at the time of this writing of $2.40. Collecting that bid as the premium represents a 13.3% return against the $18 commitment, or a 14% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to AMSC's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $18 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless American Superconductor Corp. sees its shares fall 39.6% and the contract is exercised (resulting in a cost basis of $15.60 per share before broker commissions, subtracting the $2.40 from $18), the only upside to the put seller is from collecting that premium for the 14% annualized rate of return. Below is a chart showing the trailing twelve month trading history for American Superconductor Corp., and highlighting in green where the $18 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2027 put at the $18 strike for the 14% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for American Superconductor Corp. (considering the last 250 trading day closing values as well as today's price of $30.06) to be 92%. For other put options contract idea...

The stock is near its 52-week low. Shares of Abbott Laboratories (ABT +0.77%) recently plunged after the company announced its fourth-quarter results. Over the trailing 12 months, the stock is down 16%. Some might choose to stay away from Abbott given some recent challenges. However, Abbott's stock still remains attractive, especially for dividend-seeking investors. Here is why. Abbott's quarterly update Abbott Laboratories' fourth-quarter top-line growth came up short of expectations. The company's sales were $11.5 billion, up 4.4% compared to the year-ago period. Two of the company's business segments, nutrition and diagnostics, moved in the wrong direction. And to make matters worse, the company's guidance for its fiscal 2026 was not strong either. It's not that surprising, then, that Abbott's shares fell sharply on the heels of its earnings release. Addressing the challenges It's worth pointing out, though, that Abbott's core medical device business remains strong, delivering 12.3% sales growth in the quarter. This was, once again, driven partly by its diabetes care unit, whose revenue jumped 14.5% year over year. Abbott's structural heart unit also performed pretty well. The medical device giant has plenty of growth avenues in these niches. In diabetes care, Abbott remains a leader in the CGM (continuous glucose monitoring) market thanks to its FreeStyle Libre franchise. In recent years, it has expanded its lineup, notably because of over-the-counter products such as the Libre Rio, designed for type 2 diabetes patients who aren't on insulin (CGM makers have historically targeted primarily diabetes patients on insulin), and the Lingo, which is for glucose monitoring for people who aren't diabetic. These launches expanded Abbott's addressable market. The CGM space remains deeply underpenetrated, as the company noted a few years ago. So, there could be plenty of growth left ahead for Abbott Laboratories. Expand NYSE : ABT Abbott Laboratories Today's Change ( 0.77 ...

Key Points PING Capital Management sold 269,600 shares of BBAR in the fourth quarter; the estimated transaction size was $3.87 million based on average pricing in the quarter. Meanwhile, the stake’s quarter-end value fell by $5.37 million, reflecting both trading and price movement. As of December 31, the fund reported holding 780,900 BBAR shares valued at $14.11 million. These 10 stocks could mint the next wave of millionaires › On February 2, PING Capital Management reported selling 269,600 shares of Banco BBVA Argentina (NYSE:BBAR), an estimated $3.87 million trade based on quarterly average pricing. What happened According to a February 2 SEC filing, PING Capital Management reduced its position in Banco BBVA Argentina (NYSE:BBAR) by 269,600 shares. The estimated transaction value was $3.87 million, calculated using the average closing price during the fourth quarter. Meanwhile, the fund’s quarter-end BBAR position decreased in value by $5.37 million, a figure that incorporates both share sales and price movements over the period. What else to know Following the reduction, BBAR accounted for 4.1% of the fund’s 13F AUM. Top holdings include: NYSE: YPF: $70.46 million (28.1% of AUM) NASDAQ: GGAL: $24.32 million (9.7% of AUM) NYSEMKT: KWEB: $16.85 million (6.7% of AUM) NYSEMKT: FXI: $14.36 million (5.7% of AUM) As of January 30, BBAR shares were priced at $20.22, down 9.3% over the past year and underperforming the S&P 500’s roughly 14% gain in the same period. Company overview Metric Value Revenue (TTM) $1.6 billion Net income (TTM) $178.61 million Dividend yield 1% Price (as of February 2) $20.22 Company snapshot Banco BBVA Argentina offers a full suite of retail and corporate banking products, including checking and savings accounts, time deposits, consumer and secured loans, credit cards, mortgages, insurance, and investment solutions. The company operates a broad physical and digital distribution network to provide banking, investment, and insurance products, i...

A potential merger between SpaceX and xAI could create too much uncertainty for EchoStar Corp ., according to Wall Street. SpaceX is set to acquire at least $19.6 billion worth of spectrum from EchoStar in exchange for cash and stock. But the value of that stake — and its effect on EchoStar shares — are in question following news that CEO Elon Musk is considering merging the company with one of his other ventures. A tieup with xAI is said to be in advanced talks. “Without making any judgments about SpaceX’s proposed valuation, there is at least a clear path to profitability,” MoffettNathanson analyst Craig Moffett said. “By contrast, xAI is a market laggard in a hugely concentrated market that’s burning through cash with no end in sight.” EchoStar shares have rallied about 11% since plans for a 2026 SpaceX IPO emerged in December. The stock is up about 5% Monday, after falling roughly 7% since Reuters reported last week that the company would potentially merge with xAI. Musk is also considering a SpaceX deal with Tesla Inc. , according to people familiar with the matter. READ MORE: Musk’s AI Funding Hunt Reshapes His Empire, From Tesla to SpaceX The merger speculation “muddies the waters for Echostar investors, and with a lack of information they are voting with their feet,” said UBS analyst John Hodulik . Though SpaceX has “natural synergies” with the satellite TV and wireless company, that’s not the case for large language models like xAI, according to TD Cowen analyst Gregory Williams . “Bringing LLM uncertainty into the fold creates a higher degree of risk for investors in what was otherwise a relatively straightforward satellite communications / aerospace business venture,” Williams wrote in a Jan. 29 note. It’s not just xAI’s own business model that may engender uncertainty for EchoStar, according to MoffettNathanson’s Moffett. “Just the speculation about a merger with xAI is a reminder of the highly problematic governance issues that come with being a part of...

【有線新聞】內蒙古包神鐵路7列5,000噸級貨運列車，完成全球首次多列貨運列車不靠機械掛鈎、僅靠無線信號的協同行駛試驗。 重載鐵路是國家能源運輸「大動脈」，但機械掛鈎的列車愈長，制動延遲、斷鈎脫軌的風險就愈大。擴大站場的話，成本又太高，新技術正好提供解決辦法。 重載列車群組系統項目總工程師宋宗瑩：「這7列5,000噸的重載群組列車組隊合而為一，像『鋼鐵巨龍』一樣，一趟就能運輸3.5萬噸煤炭，夠一座中型城市一周供暖用煤。我們用『技術升級』替代了『鐵路擴建』，用技術的方式破解了運能瓶頸，避免了超長列車牽引制動不同步帶來的前後車廂互相拖拽擠壓等安全風險。」 由內地自主研發全球首個重載鐵路自動編隊控制系統，精細化控制所有編組列車運行，不同型號、不同裝載、不同車站發車的列車可以隨時組隊或解編，「虛擬軟連接」亦解決了機械掛鈎的多種問題，包括超長列車常見的車廂碰撞、車鈎拉斷等。 重載列車群組系統現場試驗總指揮劉朝暉：「這套編隊控制系統就像大這套編隊控制系統腦裡『神經中樞』，對所有編組列車的運行進行精細化控制，能夠跟前車保持一個基本相同的速度，前車加速我們也加速，前車煞車我們也煞車。可以更進一步縮短車與車之間的間隔，讓重載列車的間隔距離從此前的4公里壓縮到1公里左右，時間上也從原來的10分鐘以上壓縮到了目前的5分鐘以內，實現了7列車『無線牽手』組隊高效運行。」 列車依靠「地面信號行駛」模式轉為「直接跟隨前車運行」，當群組技術普及應用，重載列車綜合運能預計會提升5成以上。

Glencore close to appointing Citi as adviser for Rio Tinto merger talks, sources say Reuters

Investors considering a purchase of ACM Research Inc (Symbol: ACMR) shares, but tentative about paying the going market price of $61.31/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $35 strike, which has a bid at the time of this writing of $6.50. Collecting that bid as the premium represents a 18.6% return against the $35 commitment, or a 9.4% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to ACMR's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $35 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless ACM Research Inc sees its shares fall 42.2% and the contract is exercised (resulting in a cost basis of $28.50 per share before broker commissions, subtracting the $6.50 from $35), the only upside to the put seller is from collecting that premium for the 9.4% annualized rate of return. Below is a chart showing the trailing twelve month trading history for ACM Research Inc, and highlighting in green where the $35 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 put at the $35 strike for the 9.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for ACM Research Inc (considering the last 250 trading day closing values as well as today's price of $61.31) to be 73%. For other put options contract ideas at the various different available expira...

Investors considering a purchase of Viasat Inc (Symbol: VSAT) stock, but cautious about paying the going market price of $46.31/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2028 put at the $15 strike, which has a bid at the time of this writing of $2.00. Collecting that bid as the premium represents a 13.3% return against the $15 commitment, or a 6.8% annualized rate of return (at Stock Options Channel we call this the). Selling a put does not give an investor access to VSAT's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $15 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Viasat Inc sees its shares fall 67.7% and the contract is exercised (resulting in a cost basis of $13.00 per share before broker commissions, subtracting the $2.00 from $15), the only upside to the put seller is from collecting that premium for the 6.8% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Viasat Inc, and highlighting in green where the $15 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 put at the $15 strike for the 6.8% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Viasat Inc (considering the last 250 trading day closing values as well as today's price of $46.31) to be 83%. For other put options contract ideas at the various different available expirations, visit the VSAT Stoc...

作者：亚历克斯・朗利、米娅・金迪斯 美国总统唐纳德・特朗普证实美方正与伊朗展开对话，地缘政治风险溢价消退，叠加大宗商品市场整体抛售潮进一步加剧，国际油价应声大幅下跌。 西德克萨斯中质原油（WTI）盘中一度暴跌超 5%，价格逼近每桶 62 美元，布伦特原油期货同样遭遇重挫。特朗普对伊朗最高领袖阿亚图拉・ 阿里 ・哈梅内伊周末发出的地区战争威胁持淡化态度，并重申仍有望与伊方达成协议。 伊朗外交部表态称，希望通过外交努力避免战争爆发。美国阿克西奥斯新闻网援引两名知情人士消息报道，白宫特使史蒂夫・维特科夫与伊朗外长阿巴斯・阿拉格希定于本周五在伊斯坦布尔举行会晤。 卡洛巴资本有限合伙公司首席投资官哈里斯・库尔希德表示：“此次油价下跌更像是市场头寸的重新调整，而非基本面的实质性转变。在没有新的供应冲击背景下，此前市场计价了短期供应中断的风险，而这一风险并未成为现实，如今油价正回吐部分风险溢价，市场也在重新校准定价。” 大宗商品市场整体承压，尤其是金属品种遭遇重挫，也进一步拖累原油价格走势。黄金价格盘中最大跌幅达 10%，铜价亦一度暴跌超 5%，延续自上周五开启的回落走势。 此次国际油价的急跌，发生在西德克萨斯中质原油录得 2023 年以来最大单月涨幅之后 —— 同期大宗商品市场迎来资金全面流入，成为油价上涨的支撑。伊朗潜在的冲突风险，以及局部地区的供应中断，使得今年首个月份的原油市场供需格局意外偏紧。但从更宏观的背景来看，原油市场供应整体处于高位，这一状况在 2026 年上半年尤为明显。 能源咨询机构 Energy Aspects 量化服务主管詹姆斯・泰勒表示，按照当前价格水平，油价的大幅反转将引发趋势跟踪型商品交易顾问（CTA）的抛售行为。他补充称，若布伦特原油价格跌破每桶 65 美元，市场抛售压力将进一步加大，同时大量未平仓期权头寸也可能加剧油价的波动幅度。 今年以来，金融资金的快速流动放大了油价的波动幅度。年初交易员持有大量原油空单，而在数周的地缘政治动荡后，这些空单被迅速平仓，头寸出现大幅反转。 责任编辑：郭明煜

Shareholders of Williams Sonoma Inc (Symbol: WSM) looking to boost their income beyond the stock's 1.3% annualized dividend yield can sell the January 2028 covered call at the $300 strike and collect the premium based on the $20.00 bid, which annualizes to an additional 4.9% rate of return against the current stock price (at Stock Options Channel we call this the), for a total of 6.2% annualized rate in the scenario where the stock is not called away. Any upside above $300 would be lost if the stock rises there and is called away, but WSM shares would have to climb 45.6% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 55.3% return from this trading level, in addition to any dividends collected before the stock was called. In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Williams Sonoma Inc, looking at the dividend history chart for WSM below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.3% annualized dividend yield. Below is a chart showing WSM's trailing twelve month trading history, with the $300 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2028 covered call at the $300 strike gives good reward for the risk of having given away the upside beyond $300. (Do most options expire worthless? This and six other common options myths debunked). We calculate the trailing twelve month volatility for Williams Sonoma Inc (considering the last 250 trading day closing values as well as today's price of $206.51) to be 42%. For other call options contract ideas at the various different available expirations, visit the WSM Stock Options page of StockOptionsChannel.com. Top YieldBoost Ca...

Kira-Yan/iStock Editorial via Getty Images On Jan. 28, 2026, Meta Platforms, Inc. ( META ) reported fourth-quarter and full-year 2025 earnings - and the numbers were impressive. For the quarter , revenue came in at $59.89 billion, which outpaced estimates by 2.43%. Diluted EPS, meanwhile, reached $8.88, surpassing estimates by 8.60%. The full-year figures are also impressive. Annual revenue and diluted EPS were $200.97 billion and $29.68, respectively, each outpacing consensus by 0.71% and 2.63%. As a result, Meta stock jumped from ~$669 per share to around $716- a roughly 7% increase. This is black and white. It's reality, all while (some) investors are still sitting on the sidelines, wondering what to do. Why do I say that? If we look at META's one-year returns, it's basically flat - weighed down by macroeconomic fears around AI spending, not by any erosion to the fundamentals. To me, this relatively rare discount seems like an ideal entry point for investors with a long-term horizon. That, and the potential growth drivers down the line, my Strong Buy rating for Meta remains in place. What Was in Meta’s Fourth Quarter and Full Year 2025 Financials? When sorting out a buy-or-not decision for any company, I like to look at what’s under the hood. For Meta, the company’s fourth-quarter 2025 revenue rose 24% to around $59.9 billion. Top-line figures were primarily driven by ad revenue, growing 24% year-over-year to $58.14 billion. Here’s a glance at Meta’s revenue breakdown for the quarter: Segment Q4 2025 Q4 2024 % Change Family of Apps - Total $58,938 $47,302 24.6% Advertising Revenue $58,137 $46,783 24.3% Other Revenue $801 $519 54.3% Reality Labs $955 $1,083 (11.8%) TOTAL REVENUE $59,893 $48,385 23.8% Click to enlarge Note: USD in Millions So far, the Reality Labs division has reported over $950 million in revenue, but that is still a decline compared to the same period last year. To me, this is a glaring sign that the consumer AR/VR market is still struggling to g...

Meta's Valuation Needs A Reality Check (NASDAQ:META) Seeking Alpha